HK1214132A1 - 用於治療α腎上腺素能受體介導的病症的化合物 - Google Patents

用於治療α腎上腺素能受體介導的病症的化合物

Info

Publication number
HK1214132A1
HK1214132A1 HK16102018.6A HK16102018A HK1214132A1 HK 1214132 A1 HK1214132 A1 HK 1214132A1 HK 16102018 A HK16102018 A HK 16102018A HK 1214132 A1 HK1214132 A1 HK 1214132A1
Authority
HK
Hong Kong
Prior art keywords
compound
mediated conditions
alpha adrenergic
treating alpha
adrenergic mediated
Prior art date
Application number
HK16102018.6A
Other languages
English (en)
Inventor
Wenkui K Fang
Phong X Nguyen
Ken Chow
Todd M Heidelbaugh
Dario G Gomez
Michael E Garst
Santosh C Sinha
Daniel W Gil
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1214132A1 publication Critical patent/HK1214132A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
HK16102018.6A 2008-06-09 2016-02-23 用於治療α腎上腺素能受體介導的病症的化合物 HK1214132A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5983708P 2008-06-09 2008-06-09

Publications (1)

Publication Number Publication Date
HK1214132A1 true HK1214132A1 (zh) 2016-07-22

Family

ID=40823137

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102018.6A HK1214132A1 (zh) 2008-06-09 2016-02-23 用於治療α腎上腺素能受體介導的病症的化合物

Country Status (15)

Country Link
US (2) US8071636B2 (zh)
EP (3) EP2303264B1 (zh)
JP (1) JP5571072B2 (zh)
CN (1) CN102099032B (zh)
AU (1) AU2009257692A1 (zh)
CA (3) CA3133261A1 (zh)
DK (2) DK2303264T3 (zh)
ES (2) ES2665293T3 (zh)
HK (1) HK1214132A1 (zh)
HU (1) HUE039357T2 (zh)
PL (2) PL2303264T3 (zh)
PT (2) PT2932968T (zh)
SI (1) SI2303264T1 (zh)
TR (1) TR201802766T4 (zh)
WO (1) WO2009152052A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US7902247B2 (en) * 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
JP5938407B2 (ja) 2010-08-16 2016-06-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ α−２Ｂアドレナリン受容体作動薬を用いて制御性Ｔ細胞を活性化する方法
RS60163B1 (sr) 2014-03-31 2020-05-29 Scripps Research Inst Farmakofor koji indukuje trail
AU2018355487B2 (en) 2017-10-27 2023-09-21 Shanghai Yao Yuan Biotechnology Co., Ltd. Compositions and methods of modulating the immune response by activating alpha protein kinase 1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6708160A (zh) * 1966-06-30 1968-01-02
DE2259160A1 (de) * 1972-12-02 1974-06-06 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline, deren saeureadditionssalze und verfahren zur herstellung derselben sowie ihre verwendung als arzneimittel
US4256755A (en) * 1980-04-28 1981-03-17 E. I. Du Pont De Nemours & Company Method of using N-substituted dihydro-2-oxazolamines as analgesics
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
EP1333028A1 (en) * 2002-01-31 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
KR20080018891A (ko) 2005-05-19 2008-02-28 바이엘 크롭사이언스 아게 살충성을 가지는 치환된 벤질아미노 헤테로사이클릭 및헤테로아릴 유도체
WO2008123821A1 (en) * 2007-03-01 2008-10-16 Albireo Ab 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders
BRPI0812840A2 (pt) * 2007-07-02 2014-12-09 Hoffmann La Roche 2-imidazolinas
US20110160265A1 (en) * 2007-10-18 2011-06-30 Luhrs Lauren M B Method of treating motor disorders with alpha-2b adrenergic receptor agonists

Also Published As

Publication number Publication date
EP2932968A1 (en) 2015-10-21
DK2932968T3 (en) 2018-03-12
JP5571072B2 (ja) 2014-08-13
CA3133261A1 (en) 2009-12-17
JP2011522893A (ja) 2011-08-04
HUE039357T2 (hu) 2018-12-28
WO2009152052A1 (en) 2009-12-17
WO2009152052A8 (en) 2010-11-11
EP2377534A1 (en) 2011-10-19
CA2744929C (en) 2017-07-25
US20120035235A1 (en) 2012-02-09
US20090306161A1 (en) 2009-12-10
PL2932968T3 (pl) 2018-06-29
PT2932968T (pt) 2018-03-13
CA2959793A1 (en) 2009-12-17
US8071636B2 (en) 2011-12-06
PL2303264T3 (pl) 2018-08-31
EP2303264A1 (en) 2011-04-06
AU2009257692A1 (en) 2009-12-17
CN102099032A (zh) 2011-06-15
ES2672777T3 (es) 2018-06-18
SI2303264T1 (en) 2018-08-31
CN102099032B (zh) 2014-07-09
DK2303264T3 (en) 2018-05-22
CA2744929A1 (en) 2009-12-17
PT2303264T (pt) 2018-05-14
EP2932968B1 (en) 2018-01-17
TR201802766T4 (tr) 2018-03-21
EP2303264B1 (en) 2018-04-04
ES2665293T3 (es) 2018-04-25

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
IL209895A0 (en) Compounds for treating beta-amyloidoses
GB0806422D0 (en) Process
GB0806419D0 (en) Process
GB0808836D0 (en) Process
IL209894A0 (en) Compounds for treating amyloidoses
HK1203516A1 (zh) 治療乾癬的方法
IL213398A0 (en) Compounds for treating cancer
GB0801209D0 (en) Process
HK1214132A1 (zh) 用於治療α腎上腺素能受體介導的病症的化合物
EP2453896A4 (en) PROCESS FOR TREATING SCHIZOPHRENIA
GB0803669D0 (en) Process
GB0801580D0 (en) Process
IL212212A0 (en) Compound useful for treating cellulite
IL211904A0 (en) Composition for treating disese
GB0800875D0 (en) Process
EP2285385A4 (en) COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
EP2296461A4 (en) METHODS OF TREATING ARTHROPODS
GB0807161D0 (en) Process
GB0808764D0 (en) Process
GB0808357D0 (en) Process
IL213287A0 (en) Treatment for glomerulonephritis
EP2325161A4 (en) METHOD FOR PRODUCING A HYDROXYESTER COMPOUND
GB0803663D0 (en) Process
EP2238120A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF A TRIPHENYLBORON PYRIDINE COMPOUND